Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
15 November 2021 - 5:29PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
15 November 2021 16:00 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 12 November 2021 an
award of AstraZeneca American Depositary Shares (ADSs) vested to Dr
Aradhana Sarin, Chief Financial Officer. Each ADS represents one
half of an Ordinary Share of $0.25 in the Company.
In accordance with the Agreement and Plan of Merger, the award was
granted under the AstraZeneca Global Restricted Stock Plan at the
time of closing of the acquisition of Alexion Pharmaceuticals, Inc.
(Alexion) by the Company. It replaced Restricted Stock Units held
by Dr Sarin under the Alexion 2017 Incentive Plan, granted in
November 2017. The replacement award vested on the completion
of the original four-year holding period.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, 5,108 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the
award was US$62.92, being the closing price on the last trading day
preceding the vesting.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Aradhana Sarin
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Financial Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
b)
|
Nature of the transaction
|
Acquisition of AstraZeneca PLC American Depository Shares pursuant
to a vesting under the Global Restricted Stock Plan
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
0
|
5,108
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
12 November 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
15 November 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024